Pfizer (NYSE:PFE) Price Target Raised to $25.00

Pfizer (NYSE:PFE) had its target price upped by UBS Group from $24.00 to $25.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the company. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 target price on the stock. Finally, Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Up 1.1 %

NYSE PFE opened at $24.19 on Wednesday. The stock has a market capitalization of $137.19 billion, a PE ratio of 17.16, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The firm has a 50 day moving average of $24.34 and a two-hundred day moving average of $25.78. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.82 EPS. As a group, research analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.11%. Pfizer’s payout ratio is currently 124.64%.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pfizer

A number of large investors have recently modified their holdings of the stock. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth approximately $27,000. Gould Capital LLC increased its stake in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the fourth quarter valued at $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.